Denton Anne, Shaw John
School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Building 505, 85 Park Road, Auckland, Grafton New Zealand.
BMC Palliat Care. 2014 Nov 18;13(1):50. doi: 10.1186/1472-684X-13-50. eCollection 2014.
Corticosteroids are commonly prescribed in palliative care for alleviation of both specific and non-specific symptoms, but relatively little is known of the perspectives of clinicians and what influences their prescribing in this context. The aim of this study was to explore the experiences and perspectives of those involved in the prescribing of corticosteroids in palliative care.
Semi-structured interviews were undertaken with 12 medical practitioners and six senior nurses from a sample of six New Zealand hospices to identify their experiences and attitudes regarding the prescribing of corticosteroids. A general inductive approach was used to thematically analyse data.
Five broad themes were identified: the role of corticosteroids in palliative care; indications for corticosteroids; influences on prescribing; use of guidelines; and perceptions of previous study data on prescribing patterns for their hospice. Interviewees regarded these agents as having an important place in in palliative care but expressed a degree of uncertainty about certain aspects of their use. They were concerned about issues such as prescribing for non-specific indications, methods of stopping, and lack of monitoring and reviewing. Guidelines were used routinely by only one of the sample hospices. Corticosteroids tended to be prescribed experientially or by habit, rather than based on evidence-based guidelines.
This study has highlighted differences in the understanding of the place of corticosteroids in palliative care by the clinicians interviewed in this study and different practices, particularly in the treatment of non-specific symptoms and in the use of guidelines. These findings suggest a need for further research and discussion about the role of corticosteroids in palliative care and the development of evidence-based guidelines to assist prescribers.
在姑息治疗中,皮质类固醇常用于缓解特定和非特定症状,但对于临床医生在此背景下的观点以及影响其处方的因素了解相对较少。本研究的目的是探讨参与姑息治疗中皮质类固醇处方的人员的经验和观点。
对来自新西兰六个临终关怀机构的12名医生和6名高级护士进行了半结构化访谈,以确定他们对皮质类固醇处方的经验和态度。采用一般归纳法对数据进行主题分析。
确定了五个广泛的主题:皮质类固醇在姑息治疗中的作用;皮质类固醇的适应症;对处方的影响;指南的使用;以及对其临终关怀机构先前关于处方模式研究数据的看法。受访者认为这些药物在姑息治疗中占有重要地位,但对其使用的某些方面表示一定程度的不确定性。他们担心非特定适应症的处方、停药方法以及缺乏监测和复查等问题。样本临终关怀机构中只有一家常规使用指南。皮质类固醇的处方往往基于经验或习惯,而非基于循证指南。
本研究突出了本研究中受访临床医生对皮质类固醇在姑息治疗中地位的理解差异以及不同的做法,特别是在非特定症状的治疗和指南的使用方面。这些发现表明需要进一步研究和讨论皮质类固醇在姑息治疗中的作用,并制定循证指南以协助处方者。